Founded in 2004, DIURNAL® , a NEUROCRINE BIOSCIENCES® Company, is a European, UK-headquartered specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency.
Our expertise and innovative research activities focus on circadian-based endocrinology (mimicking the body's natural hormone levels) to develop products for rare and chronic endocrine conditions
Partnering and business development is integral to our strategy of building a leading pharmaceutical company. We forge creative partnerships with other innovative companies that advance our business.
Effective 1 November 2022, Diurnal Limited has been acquired by Neurocrine Biosciences Inc
View all historical press releases in the News section. Effective 1 November 2022, Diurnal Limited has been acquired by Neurocrine Biosciences Inc.
Diurnal is a rapidly growing global specialty pharmaceutical company with a highly integrated and very committed team. We're always looking for talented individuals who share our vision.
Diurnal is committed to transparency in its interactions. Diurnal commits to following relevant pharmaceutical codes and has published details of its transfers of value below. Where individual countries have other transparency regulations, Diurnal's declarations for these can be found in the Transparency dropdown menu on a country-specific basis.
Diurnal is committed to transparency in clinical trials and publishes the protocols and results of its clinical trials on the website www.clinicaltrials.gov